Azenta
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, As...
Latest News
5 days ago · fool.com
Why Azenta Stock Crushed it on WednesdayWednesday was an ideal day to be invested in Azenta's (AZTA +20.80%) stock. Investors fell over themselves buying shares of the healthcare tech company, and when the scramble subsided, the stock had gained almost 21%.
5 days ago · marketbeat.com
What Azenta (AZTA) Said on Its Q4 Earnings CallAzenta NASDAQ: AZTA forecast faster organic revenue growth and higher profitability for fiscal 2027 after fourth-quarter sales exceeded expectations, as the company works to improve its automated storage business and expand its gene synthesis capabilities.
5 days ago · seekingalpha.com
Azenta, Inc. (AZTA) Q4 2026 Earnings Call TranscriptAzenta, Inc. ( AZTA ) Q4 2026 Earnings Call November 11, 2026 8:30 AM EST Company Participants Yvonne Perron - Vice President of Financial Planning & Analysis and Investor Relations Martin Madaus - Interim President, CEO & Director William Martin - Senior Vice President & President of Multiomics Lawrence Lin - Executive VP & CFO Conference Call Participants David Saxon - Needham & Company, LLC, Research Division Matthew Stanton - Jefferies LLC, Research Division Steven Etoch - Stephens Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Parisi - KeyBanc Capital Markets Inc., Research Division Brendan Smith - TD Cowen, Research Division Presentation Operator Greetings, and welcome to Azenta Fourth Quarter 2026 Fiscal Financial Results. [Operator Instructions] As a reminder, this conference is being recorded, Wednesday, November 11, 2026.
6 days ago · prnewswire.com
Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.Q4'26 reported revenue growth of 5% year over year and 2% on an organic basis FY'26 reported revenue growth of 5% year over year and 2% on an organic basis FY'27 reported revenue expected to range from $648 to $660 million FY'27 organic revenue growth expected to range between 3% to 5% year over year FY'27 adjusted EBITDA margin expected to expand approximately 200 to 250 basis points year over year BURLINGTON, Mass., Nov. 10, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2026.
14 days ago · seekingalpha.com
Azenta: A Sample Custody Annuity Priced Like A Broken Equipment VendorAzenta is undervalued, with 30% of its market cap in cash and a strong recurring revenue base overlooked due to capital equipment struggles. Recurring streams now exceed 50% of revenue, and the annuity-like custody and consumables business is masked by temporary hardware margin compression. Leadership transition introduces uncertainty, but the interim CEO's track record and portfolio simplification signal potential for disciplined capital allocation and margin expansion.
18 days ago · prnewswire.com
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis CapabilitiesExclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GENEWIZ for long-term growth BURLINGTON, Mass., Oct. 30, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced strategic investments to advance the next phase of growth for its GENEWIZ business.
19 days ago · prnewswire.com
Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Conference Call and WebcastBURLINGTON, Mass., Oct. 28, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2026 earnings which ended on September 30, 2026, on Tuesday, November 10, 2026, after the market closes.
1 month ago · gurufocus.com
Azenta Inc (AZTA) Shares Fall 7.9% -- What GF Score of 83 Tells InvestorsOn October 06, 2026, Azenta Inc (AZTA) shares fell 7.9% today, currently priced at $39.35. This move comes amid a 52-week range of $15.93 to $46.41, reflecting
2 months ago · prnewswire.com
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical SystemsBURLINGTON, Mass., Sept. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.
3 months ago · prnewswire.com
AZENTA ANNOUNCES LEADERSHIP TRANSITIONCurrent Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AZTA